Images List Premium Download Classic

Steatohepatitis

Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Aryl acylsulfonamides as blt1 antagonists
October 11, 2018 - N°20180291017

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene b4 receptor 1 (blt1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene b4 receptor 1 (blt1). The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid ...
Ask1 inhibitor compounds and uses thereof
October 11, 2018 - N°20180291002

Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.. .
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
September 27, 2018 - N°20180273955

The invention relates to double stranded ribonucleic acid (dsrnai) agents and compositions targeting the scap gene, as well as methods of inhibiting expression of a scap gene and methods of treating subjects having a scap-associated disorder, such as nonalcoholic fatty liver disease (nafld) or nonalcoholic steatohepatitis (nash), using such dsrnai agents and compositions.. .
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
September 13, 2018 - N°20180259537

Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (nafld) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided.
Cb2 receptor internalization
Arena Pharmaceuticals, Inc.
September 06, 2018 - N°20180252736

Certain compounds and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor, including its internalization in a cell, are provided. Certain methods of identifying compounds that increase cb2 receptor internalization are also provided.
Gene signatures of inflammatory disorders that relate to the liver
Nstitut National De La Recherche Agronomique
September 06, 2018 - N°20180251819

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
Eiger Group International, Inc.
July 19, 2018 - N°20180200228

Disclosed herein are methods for use of r-chloroquine or clemizole or combinations of r-chloroquine and clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory′ conditions, treating liver cancer or reducing the risk of developing liver cancer in a subject.
Systems, devices and methods for performing medical procedures in the intestine
Fractyl Laboratories, Inc.
July 12, 2018 - N°20180193590

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
The University Of British Columbia
July 12, 2018 - N°20180193413

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive ...
Fatty acid amides for the prevention and/or treatment of steatohepatitis
FundaciÓ Institut Mar D'investigacions MÈdiques
July 12, 2018 - N°20180193293

The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis ...
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
July 05, 2018 - N°20180185330

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Compositions and methods for the reduction or prevention of hepatic steatosis
Nusirt Sciences, Inc.
June 21, 2018 - N°20180169043

Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof.
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty ...
Metabolic Technologies, Inc.
June 07, 2018 - N°20180153827

Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (nafld), alcoholic liver disease (ald) or nonalcoholic steatohepatitis (nash), are described. The compounds of the present invention are gamma-ketoaldehyde scavengers..
Method for screening pharmaceuticals for treatment of steatohepatitis using n-terminal dimerization of apoptosis signal-regulated kinase1
Wuhan University
May 31, 2018 - N°20180149638

A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing n-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.. .
Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention ...
Pierre Fabre Medicament
May 24, 2018 - N°20180140609

The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.. .
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
May 10, 2018 - N°20180125870

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Treatment for hepatic fibrosis
Galmed Research And Development Ltd.
May 10, 2018 - N°20180125862

The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), employing the use of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (...
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
Askat Inc.
May 10, 2018 - N°20180125832

This invention is directed to prostaglandin e2 receptor 4 (ep4) antagonists useful in the treatment of nonalcoholic steatohepatitis (nash)-associated liver cancer in a human or animal. The method comprises administering one or more of compound a, compound b or compound c, or pharmaceutically acceptable salts thereof, as the ep4 antagonist(s).
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical ...
Deuterx, Llc
May 03, 2018 - N°20180117026

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.. .
Methods of treating liver disease using indane acetic acid derivatives
T3d Therapeutics, Inc.
May 03, 2018 - N°20180117013

This invention describes the use of indane acetic acid derivatives which are dual ppar delta/gamma agonists for the treatment of liver diseases including one or more of the following: nafld (non alcoholic fatty liver disease), nash (non alcoholic steatohepatitis), farber's disease, aclf (acute-on-chronic liver failure), clf (chronic liver failure), polt-hcv-svr (post-orthotopic liver transplant due to hepatitis c virus infection ...
Loading